What is the first-line nonsteroidal anti-inflammatory drug (NSAID) treatment for gout?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 25, 2025 • View editorial policy

From the Guidelines

Naproxen is generally considered the preferred NSAID for acute gout flares, typically dosed at 500mg twice daily until the flare resolves. This recommendation is based on high-quality evidence from recent studies, including those published in the Annals of Internal Medicine 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Indomethacin (50mg three times daily) has traditionally been used but carries more side effects. Celecoxib (400mg initially, then 200mg twice daily) is an alternative for patients with gastrointestinal risk factors. Any NSAID should be used at the maximum recommended dose for quick symptom relief and continued until the flare completely resolves, usually 5-7 days. Some key points to consider when treating acute gout flares include:

  • NSAIDs work by inhibiting prostaglandin synthesis, reducing inflammation in the affected joint.
  • Always take NSAIDs with food to minimize gastrointestinal side effects.
  • Avoid NSAIDs if you have kidney disease, heart failure, or a history of gastrointestinal bleeding.
  • For patients who cannot take NSAIDs, colchicine or corticosteroids are alternative first-line options.
  • Remember to stay well-hydrated and rest the affected joint during treatment. It's also important to note that lifestyle modifications, such as weight loss, avoidance of alcohol and sugar-sweetened drinks, and regular exercise, can help reduce the risk of gout attacks 10.

From the FDA Drug Label

Indomethacin capsules have been found effective in relieving the pain, reducing the fever, swelling, redness, and tenderness of acute gouty arthritis In patients with acute gout, a favorable response to naproxen was shown by significant clearing of inflammatory changes (e.g., decrease in swelling, heat) within 24 to 48 hours, as well as by relief of pain and tenderness.

First-line treatment for gout:

  • Both indomethacin 11 and naproxen 12 are effective in treating acute gouty arthritis.
  • Indomethacin is a potent inhibitor of prostaglandin synthesis, which may contribute to its effectiveness in relieving symptoms of gout.
  • Naproxen has been shown to be as effective as aspirin in controlling disease activity, but with fewer side effects. It is not possible to determine which NSAID is best for 1st line treatment of gout based on the provided information.

From the Research

First-Line Treatment for Gout

The first-line treatment for gout typically involves the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids 13.

NSAIDs for Gout Treatment

Several studies have compared the efficacy of different NSAIDs in the treatment of acute gout.

  • A study comparing etoricoxib 120 mg once daily with indomethacin 50 mg three times daily found that etoricoxib was comparable in efficacy to indomethacin, with a lower incidence of adverse events 14.
  • Another study comparing lumiracoxib 400 mg once daily with indomethacin 50 mg three times daily found that lumiracoxib had comparable efficacy to indomethacin, with a better safety and tolerability profile 15.
  • However, it is essential to note that the choice of NSAID may depend on individual patient factors, such as renal function and gastrointestinal risk 13.

Comparison of NSAIDs

The available evidence suggests that:

  • Etoricoxib and lumiracoxib may be effective alternatives to indomethacin for the treatment of acute gout, with potentially better safety profiles 14, 15.
  • However, there is limited direct comparison between different NSAIDs, and the choice of NSAID may depend on individual patient factors and clinical judgment 13.

Key Findings

  • NSAIDs, such as etoricoxib and lumiracoxib, are effective for the treatment of acute gout, with comparable efficacy to indomethacin 14, 15.
  • The choice of NSAID should be individualized based on patient factors, such as renal function and gastrointestinal risk 13.

References

Research

What's new on the front-line of gout pharmacotherapy?

Expert opinion on pharmacotherapy, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.